TY - JOUR T1 - Probiotics, prematurity and neurodevelopment: follow-up of a randomised trial JF - BMJ Paediatrics Open DO - 10.1136/bmjpo-2017-000176 VL - 1 IS - 1 SP - e000176 AU - Susan E Jacobs AU - Leah Hickey AU - Susan Donath AU - Gillian F Opie AU - Peter J Anderson AU - Suzanne M Garland AU - Jeanie L Y Cheong A2 - , Y1 - 2017/11/01 UR - http://bmjpaedsopen.bmj.com/content/1/1/e000176.abstract N2 - Objective To determine the impact of one probiotics combination on the neurodevelopment of very preterm children at 2–5 years corrected gestational age (CA).Design Follow-up study of survivors of a double-blinded, placebo-controlled, randomised trial of probiotic effects on late-onset sepsis in very preterm infants that found reduced necrotising enterocolitis.Setting 10 tertiary perinatal centres in Australia and New Zealand.Patients 1099 very preterm infants born <32 weeks’ gestation and weighing <1500 g.Intervention Probiotics (Bifidobacterium infantis, Streptococcus thermophilus and Bifidobacterium lactis) or placebo administered from birth until discharge home or term CA, whichever came sooner.Main outcome measures Major neurodevelopmental impairment comprised any of moderate/severe cerebral palsy (Gross Motor Function Classification System score 2–5), motor impairment (Bayley-III Motor Composite Scale <–2SD or Movement Assessment Battery for Children <15th centile if >42 months’ CA), cognitive impairment (Bayley-III Composite Cognitive or Language Scales <–2SD or Wechsler Preschool and Primary Scale of Intelligence Full Scale Intelligence Quotient <–2SD if >42 months’ CA), blindness or deafness.Results Outcome data were available for 735 (67%) participants, with 71 deaths and 664/1028 survivors assessed at a mean age of 30 months. Survival free of major neurodevelopmental impairment was comparable between groups (probiotics 281 (75.3%) vs placebo 271 (74.9%); relative risk 1.01 (95% CI 0.93 to 1.09)). Rates of deafness were lower in probiotic-treated children (0.6% vs 3.4%).Conclusion Administration of the probiotics combination Bifidobacterium infantis, Streptococcus thermophilus and Bifidobacterium lactis to very preterm babies from soon after birth until discharge home or term CA did not adversely affect neurodevelopment or behaviour in early childhood.Trial registration number Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN012607000144415. ER -